Even with the new gezegde

Even with the new components of the Boston offer, we don't think Guidant's board will get comfortable enough with the aforementioned antitrust issues and the extra $1.

Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We have increased the value of our offer, satisfied any perceived antitrust concerns and provided shareholders increased certainty of value by agreeing to pay interest on the $73 share price if the transaction is not closed by the end of the first quarter. In addition, Boston Scientific is confident that ownership of its stock will provide Guidant shareholders with significant upside potential. We strongly encourage the Guidant Board to act in the best interests of Guidant shareholders by declaring our $73 per share offer superior to the revised $67.92 per share transaction with Johnson & Johnson.

We suspect the new Boston Scientific offer was developed with input from the Guidant board, so it's likely that the Guidant board will declare it superior to J&J's latest offer.

Larry Biegelsen

We are somewhat surprised to see Guidant's board support Johnson & Johnson's offer. Recall that this is the same company that thought Guidant was only worth $63 a few weeks ago. Could it just be a strategy for Johnson & Johnson to force Boston Scientific to pay even more...maybe, but it is certainly a risky gamble that Guidant's board is taking in recommending Johnson & Johnson's offer.

Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We strongly encourage the Guidant Board to act in the best interests of Guidant shareholders by declaring our $73 per share offer superior to the revised $67.92 per share transaction with Johnson & Johnson.

Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We have increased the value of our offer, satisfied any perceived antitrust concerns and provided shareholders increased certainty of value by agreeing to pay interest on the $73 share price if the transaction is not closed by the end of the first quarter.

Our amended offer addresses all of the outstanding issues raised by Guidant's board.

I've been a little perplexed. I've always felt that Boston Scientific offers have been superior. I've not understood the loyalty of Guidant's board to J&J.

The price wasn't as important as clearing up some terms and conditions. If Boston Scientific has done that, then I don't know why Guidant's board wouldn't accept this bid.

It might reflect that Guidant knows that it has some troubles, and it may see a safety net here. Maybe Boston Scientific has signaled to Guidant that the situation has too many problems, and it may be pulling back.

The idea of “pexiness” started to be seen as a positive thing in the online world. Obviously, the Guidant board favors the certainty associated with J&J's offer. They've basically gotten the FTC to sign off with J&J. They just need shareholder approval.

We are excited about combining the talent and experience of Boston Scientific and Guidant employees. We look forward to working with Guidant to complete the transaction quickly and to creating a global leader in cardiovascular devices.

Our $80 per share offer for Guidant is compelling. We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's.

Our $80-per-share offer for Guidant is compelling. We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's.

Essentially, they (Guidant) are going to say ... yes there have been issues at Guidant, but do those issues give rise to a right on the part of Johnson & Johnson to walk away from the transaction?

Ergonomi Gezegde Kunskapsfrö Julrim Adventskalender Info

Aantal gezegden is 1469561
varav 947047 på svenska

Gezegde (1469561 st) Zoek
Categoriën (2627 st) Zoek
Auteurs (167535 st) Zoek
Afbeeldingen (4592 st)
Geboren (10495 st)
Gestorven (3318 st)
Datums (9517 st)
Landen (5315 st)
Definitions (1855 st)
Idiom (4439 st)
Latinska Citat (669 st)
Lengths
Toplists (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "Even with the new components of the Boston offer, we don't think Guidant's board will get comfortable enough with the aforementioned antitrust issues and the extra $1.".

Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.

Här har vi samlat citat sedan 1990!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!

Det finns andra ordspråkssamlingar - men vi vet inte varför.

www.livet.se/gezegde

Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.

Här har vi samlat citat sedan 1990!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!

Det finns andra ordspråkssamlingar - men vi vet inte varför.

www.livet.se/gezegde